FLASH proton therapy preserved ocular function without reducing short-term tumor control
FLASH protons largely preserved ocular structure and retinal function after 24 Gy while maintaining short-term tumor control in mice.
FLASH protons largely preserved ocular structure and retinal function after 24 Gy while maintaining short-term tumor control in mice.
Four-year biochemical control was similar with 65 Gy in 26 fractions and 66 Gy in 33 fractions, while gastrointestinal toxicity was higher.
Across 187 fractions, surface-guided breath-hold IMPT remained highly stable, with only one patient requiring adaptive replanning.
VMAT exposed less circulating blood than IMRT, but modeled immune-cell depletion differed by only one percentage point after 30 fractions.
A six-center end-to-end framework detected anatomy-induced proton dose deterioration and verified near-complete recovery after adaptive replanning.
Across 127 studies, CBCT-guided online adaptation repeatedly improved target coverage and OAR sparing, while evidence for better clinical outcomes remained sparse.
Dynamic tangential IMRT delivered left-breast DIBH 42% faster than VMAT with similar target coverage and lower low-dose normal-tissue exposure.
AI-generated synthetic CT achieved 99.8% gamma agreement with conventional CT while automated pelvic contours remained within expert interobserver variability.
No prospective trial has established the safety of combining partial breast irradiation with sentinel lymph node biopsy omission in early breast cancer.
Spatially fractionated radiotherapy relieved symptoms in 91.7% of patients with bulky advanced tumors without reported grade ≥3 toxicity.
Neoadjuvant chemoradiotherapy achieved 26.5% pathological complete response and 80.4% five-year survival, outperforming chemotherapy-based strategies in this retrospective cohort.
Boosting selected proton spots reduced simulated prompt-gamma noise by up to 93.3% while maintaining acceptable target and organ-at-risk dosimetry.
Twelve-month TME-free survival was 78.5% with long-course chemoradiotherapy versus 60.6% with short-course radiotherapy in early rectal cancer.
Across five phase III trials, whole-pelvic radiotherapy did not improve overall survival, and progression benefits disappeared when POP-RT was excluded.
Postoperative proton therapy achieved 84% five-year local control in paediatric ependymoma